BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24280934)

  • 21. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
    Borovecki A; Skrtić A; Paro MM; Lasan R; Dominis M
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
    Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
    Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
    Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
    Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
    Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
    Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
    Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis.
    Florena AM; Tripodo C; Di Bernardo A; Iannitto E; Guarnotta C; Porcasi R; Ingrao S; Abbadessa V; Franco V
    J Clin Pathol; 2009 Apr; 62(4):331-8. PubMed ID: 19329711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant proplatelet formation in chronic myeloproliferative neoplasms.
    Muth M; Büsche G; Bock O; Hussein K; Kreipe H
    Leuk Res; 2010 Nov; 34(11):1424-9. PubMed ID: 20430444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Megakaryocytic expression of miRNA 10a, 17-5p, 20a and 126 in Philadelphia chromosome-negative myeloproliferative neoplasm.
    Hussein K; Dralle W; Theophile K; Kreipe H; Bock O
    Ann Hematol; 2009 Apr; 88(4):325-32. PubMed ID: 18773208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study.
    Subotički T; Mitrović Ajtić O; Mićić M; Kravić Stevović T; Đikić D; Diklić M; Leković D; Gotić M; Čokić VP
    Ultrastruct Pathol; 2018; 42(6):498-507. PubMed ID: 30582392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases.
    Tognon R; Gasparotto EP; Leroy JM; Oliveira GL; Neves RP; Carrara Rde C; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Velano CE; Simões BP; Alberto FL; Miyashiro K; de Souza AM; Amarante-Mendes GP; de Castro FA
    J Clin Pathol; 2011 Jan; 64(1):75-82. PubMed ID: 21045235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.
    Stauffer Larsen T; Hasselbalch HC; Pallisgaard N; Møller MB
    APMIS; 2007 Nov; 115(11):1267-73. PubMed ID: 18092959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2
    Zhan H; Ma Y; Lin CH; Kaushansky K
    Leukemia; 2016 Dec; 30(12):2332-2341. PubMed ID: 27133820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.
    Lekovic D; Gotic M; Skoda R; Beleslin-Cokic B; Milic N; Mitrovic-Ajtic O; Nienhold R; Sefer D; Suboticki T; Buac M; Markovic D; Diklic M; Cokic VP
    Ann Hematol; 2017 Mar; 96(3):393-404. PubMed ID: 27924369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.